Apaf-1 Caspase-9 Cyt c control sulindac control E LY294002 control TRAIL thapsigargin HT-29Chondrocyte control SIN-1 RAW 264.7 IP: AChE C Supplementary.

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

Caspases in p75-mediated Neuronal Death Pathway. Cell Death Necrosis –Response to disease –Inflammatory Response Apoptosis –Present in Developing Tissue.

Suppl. Fig TET -  -Flag  -Tub Flag-TDP-43WT Flag-TDP-12xQ/N.

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

ANTHRAX. LF EF TRAF6 TAK1 MKK3,6 p38 Targets Stimulus Activator MKKK MKK MAPK Targets LT = PA + LF ET = PA + EF Zinc metalloprotease TRAF2 MEKK1,

Perpendicular Lines. What is to be learned? The rule connecting gradients and perpendicular lines.

Fig. 16-CO, p Fig. 16-1, p. 450 Fig. 16-2, p. 450.

Slide 1Fig. 10.1, p.293. Slide 2Fig. 10.1a, p.293.

Slide 1Fig. 5.1, p.113. Slide 2Fig. 5.1a, p.113 Slide 3Fig. 5.1b, p.113.

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

Figure 1.1 The observer in the truck sees the ball move in a vertical path when thrown upward. (b) The Earth observer views the path of the ball as a parabola.

Supplementary Fig. 1. (a) Cells were treated with DMSO or with 1 µM of SK-7068 or LAQ824 for 18 hours. They were then fixed with 70% ethanol, stained with.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Slide 1Fig 28-CO, p.858. Slide 2Fig 28-1, p.859 Slide 3Fig Q28-19, p.884.

FSCCD40 mediumFluCL %82 %97 % SSC FSC GEN2.2 cells B mediumFluCL097CpG ACpG B GEN2.2 GENshTLR7 % CD40 positive cells TLR7TLR9 0.0.

PrimerSequence (5' to 3')Comments Hpt-FwCGCGACGTCTGTCGAGAAGTTT RT-PCR analysis Hpt-RvATCGGACGATTGCGTCGCATCGA RT-PCR analysis AOX1a-FwGATGTTTGTCTACTGCCGAGGATTT.

Supplementary table 1. Supplementary table 2 Supplementary table 3.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Vijaya Ramachandran Fig S1 D C Supplementary Figures Invasion Apoptosis A Proliferation BxPC % of Viable Cells  AGR2(nM)

Nardella et al. Supplementary Fig. 1 Murine Rheb wt Line 47 Line 50 Log gene expression (a.u.) ******* 200 bp Founders

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplementary Fig. 1 APACHE II score ( transformed) SOFA score (transformed)

 Almost all other countries are using the metric system  Other countries’ companies are refusing to buy products from the U.S. if not labeled in metric.

CD8 CD4 IgM B220 ThymusA. C.BM D. LN CD4 CD8 CD43 B220 IgM Spleen counts B220 IgD E. F. Kim et al._Fig. S1. PIDD +/+PIDD -/- Spleen CD44 CD25 Gated on.

江苏建筑职业技术学院图书馆新生入馆教育. 目录页 CONTENTS PAGE P1. 图书馆概况 P2. 关于借书二、三事 P3. 电子资源推介与使用.

SA-β-Gal positivity (%) Days after 6 Gy of IR exposure 3 Morphology SA-  -Gal 015 Supplementary Fig. S1 A B.

Novel agents targeting the apoptosis pathway Aaron D. Schimmer MD, PhD, FRCPC Princess Margaret Hospital Toronto, Canada.

The reading is 7.38 mm. The reading is 7.72 mm.

A B Pax8 CK7 CA125 HE4 HE xenograft tumor primary #20 bright phase HE

Supplementary Fig. 1 *** Cell viability (%) HepG2 3 (hr) DU145 A549 17

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Fig. 1. Neem induces caspase-3 activation and cell death in multiple cancer cell types. ( A ) HCT116 cells were treated with neem for 0, 12, 24 and 36h,

Mel501 Supplementary 1A Caspase 8 activity % 24h Caspase 9 activity %

Supplementary figures

500 mg total protein /mL S-CM 250 mg total protein /mL S-CM

Suppl. Fig. 1 A B C No tumor - +

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

الاسبوع الإرشادي.

A IP: Proteintech anti-SK2 B IP: Proteintech anti-SK2 Ab SK2 IgG

(6h ) Supplemental Fig. 2 a. 32Dp210 b. 32Dp210 c. 32DP210

A B HT29 HCT15 Colo205 Ls174T LS180 Isotypic control

Supplementary information

A B Supplementary Figure 3

Altankasser og ampel.

Supplementary Figure S1

Example: If line AB is parallel to line CD and s is parallel to t, find the measure of all the angles when m< 1 = 100°. Justify your answers. t

Interleukin-1β and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation

Glutamine protects articular chondrocytes from heat stress and NO-induced apoptosis with HSP70 expression H. Tonomura, M.D., K.A. Takahashi, M.D., Ph.D.,

GEOMETRICAL CONCEPTS LINE SEGMENT

Supplementary Figure S1

Suppl. Fig. 2 A B Evaluation of FasL-induced apoptosis in BM-MSCs.

Abemaciclib (µM) LY (µM)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

IL-10 upregulates IgG4 production by CD27+ B cells.

Hylder og ophængs- kroge

Desiccating stress worsens alkali burn injury by magnifying caspase-8-induced imbalance of NLRP3 and NLRP6 Xia Hua, MD, PhD, Xiaoyong Yuan, MD, PhD,

A B Supplementary Figure S1 PC3 cells Vehicle 3β-Adiol

Mutant Alanine Position

Detection of exosomal proteins using magnetic particles

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Fig. 1. Effects on the tight junction barrier and permeability following doxorubicin and Herceptin treatment. Effects on the tight junction barrier and.

Downregulation of inhibitor of apoptosis proteins in apoptotic human chondrocytes treated with tumor necrosis factor-alpha and actinomycin D Dr F. Yoshimura,

Inhibition of polymerization Enhancement of polymerization

A B D C E F Supplementary Figure S4. Epping et al. IP: flag input IgG

Fig. 2 Contribution of SQSTM1 to the autophagic degradation of ARNTL.

Presentation transcript:

Apaf-1 Caspase-9 Cyt c control sulindac control E LY control TRAIL thapsigargin HT-29Chondrocyte control SIN-1 RAW IP: AChE C Supplementary Fig. S1 AB IP : Apaf-1 WB: AChE IP: Caspase-3 WB: AChE IP: Caspase-9 WB: AChE IP: c-IAP-1 WB: AChE IP: c-IAP-2 WB: AChE IP: Cyt c WB: AChE E treated Thapsigargin 2.5  M, 24 h HT-29 Sulindac 1 mM, 48 h E40 40 h LY  M, 24 h TE671 BMMC U373MG E50 24 h E40 24 h SK-MEL5 E10 48 h RAW SIN-1 1 mM, 24 h IL-3 deprivation Malme-3M E50 24 h TRAIL 100 MOI, 72 h Chondrocyte SNP 1.5 mM, 24 h  -actin control treated

E40 si Cyt c Cyt c Hoechst A Supplementary Fig. S2 B si Cyt c h Chondrocyte TRAIL 100 MOI HT-29 Thapsigargin 2.5  M Apaf-1 IP: AChE IgG IP: Apaf-1 WB: Apaf-1 IP: Apaf-1 WB: Apaf-1 IgG PC IP: AChE SK-MEL-5 E10 RAW SIN-1 1 mM h Apaf-1 IgG si Cyt c IP: Apaf-1 WB: Apaf-1 IP: Apaf-1 WB: Apaf-1 PC

Supplementary Fig. S3 IP : Cav-1 E h AChE IgG A B si Cyt c E h IP: Cav-1 IgG AChE C D IP: Apaf-1 WB: AChE E50 (LNCaP)E10 (PC-3) h IP: Cav-1 WB: AChE IP: Cyt c WB: AChE IP: Cyt c WB: Apaf-1 IP: Apaf-1 WB: AChE IP: Cav-1 WB: AChE IP: Cyt c WB: AChE IP: Cyt c WB: Apaf-1 IP: AChE WB: AChE IP: AChE WB: AChE IP: AChE WB: AChE IP: Apaf-1 WB: Apaf-1 IP: AChE WB: AChE IP: AChE WB: AChE IP: AChE WB: AChE IP: Apaf-1 WB: Apaf-1 PC IgG E h IgG Apaf-1 Cyt c IP: Cav-1 IP: Apaf-1 WB: Apaf-1 IP: Cyt c WB: Cyt c IgG PC E IP: Cav-1 M  CD E / h AChE IP: Apaf-1 AChE Cyt c IgG IP: Cyt c